ACADIA Pharmaceuticals Inc. 3Y Total Assets Growth (CAGR)

3Y Total Assets Growth (CAGR) of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including 3Y Total Assets Growth (CAGR) growth rates and interactive chart.


Highlights and Quick Summary

  • Annual 3Y Total Assets Growth (CAGR) for 2020 was 26.73% (a 127.49% increase from previous year)
  • Annual 3Y Total Assets Growth (CAGR) for 2019 was 11.75% (a -65.96% decrease from previous year)
  • Annual 3Y Total Assets Growth (CAGR) for 2018 was 34.52% (a 504.55% increase from previous year)
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical 3Y Total Assets Growth (CAGR) of ACADIA Pharmaceuticals Inc.

Most recent 3Y Total Assets Growth (CAGR)of ACAD including historical data for past 10 years.

Interactive Chart of 3Y Total Assets Growth (CAGR) of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. 3Y Total Assets Growth (CAGR) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 26.73%
2019 11.75%
2018 34.52%
2017 5.71%
2016 43.7%
2015 26.9%
2014 116.4%
2013 70.15%
2012 29.78%

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.